According to Vanda Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $0.19 B. In 2022 the company made a revenue of $0.25 B a decrease over the years 2021 revenue that were of $0.26 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.19 B | -24.27% |
2022 | $0.25 B | -5.32% |
2021 | $0.26 B | 8.27% |
2020 | $0.24 B | 9.23% |
2019 | $0.22 B | 17.64% |
2018 | $0.19 B | 16.98% |
2017 | $0.16 B | 13.06% |
2016 | $0.14 B | 32.83% |
2015 | $0.10 B | 119.17% |
2014 | $50.15 M | 48.04% |
2013 | $33.87 M | 3.52% |
2012 | $32.72 M | 4.66% |
2011 | $31.27 M | -12.43% |
2010 | $35.7 M | 685.2% |
2009 | $4.54 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 48,188.00% | ๐บ๐ธ USA |
Novartis NVS | $49.92 B | 25,815.70% | ๐จ๐ญ Switzerland |
Pfizer PFE | $58.49 B | 30,265.97% | ๐บ๐ธ USA |
Eli Lilly LLY | $34.12 B | 17,613.92% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 31,105.36% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.53 B | 23,536.84% | ๐บ๐ธ USA |
Titan Pharmaceuticals
TTNP | $0 M | -100.00% | ๐บ๐ธ USA |